A study released by D Yellow Elephant has suggested that both multinational and domestic pharmaceutical firms in India are avoiding the opportunities that digital platforms create. The study, conducted by a team of researchers from Delhi University, found that while global companies like Pfizer have been investing heavily into developing new medicines for India, they were not doing so at an appropriate pace.
A study released by D Yellow Elephant has suggested that both multinational and domestic pharmaceutical firms in India are avoiding the opportunities that digital platforms create. Only 14 companies out of 40 polled, have an active LinkedIn presence and only 30% have a website, highlighting that there is room for significant growth in this area.